Skip to content
Subscriber Only

Takeda to Sell Consumer Unit to Blackstone for $2.3 Billion

  • Blackstone to invest 50 billion yen into unit with IPO plan
  • Sale is part of Takeda’s goal of $10 billion in asset disposal
Takeda Pharmaceutical CEO Christophe Weber News Conference
Photographer: Kiyoshi Ota/Bloomberg
Updated on

Takeda Pharmaceutical Co. agreed to sell its Japanese consumer health-care business for 242 billion yen ($2.3 billion) to Blackstone Group Inc., which plans to take the over-the-counter medication unit public in about five years.

For the drugmaker, the sale represents another piece of its plan to dispose $10 billion in assets after its $62 billion mega-acquisition of Shire Plc last year.